Microdosing glp-1 is gaining traction, but is it safe? Experts warn about compounded semaglutide, reduced efficacy, and ...

Natco Pharma and Dr. Reddy's Laboratories are eyeing blockbuster drug–Novo Nordisk’s breakout star Semaglutide, sold under ...

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

Unlike other slimming injections, the jab manufactured by US pharmaceutical giant Eli Lilly not only suppresses the appetite ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Researchers said the study backs up anecdotal evidence from patients and doctors that semaglutide can lead to a sudden loss of longing for alcoholic drinks ...

A new study has found that semaglutide — the active substance in Ozempic and Wegovy — may help reduce alcohol cravings in people with AUD. Despite the availability of treatment options ...

Between 2018 and 2024, China has launched 188 domestically developed innovative drugs – nearly double the number from the ...

In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...